

# **Investor Update**

May 27, 2019

LOOKING AT MENTAL HEALTH, OBJECTIVELY

#### **Forward Looking Statements**

The purpose of the presentation is to provide an update of the business of Medibio Limited (ASX:MEB) (OTCQB: MDBIF). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification.

Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Medibio Limited and should not be relied upon as an independent source of information. Please contact Medibio Limited and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified.

None of Medibio Limited, or any of its affiliates or associated companies (or any of their officers, employees, contractors or agents (the Relevant Persons)) makes any representation or warranty as to the accuracy, completeness or reliability of the information, or the likelihood of fulfillment of any forward looking statement or any outcomes expressed or implied in any forward looking statements.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Medibio Limited's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks.

Because actual results could differ materially to assumptions made and Medibio Limited's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. Except as required by applicable law or the ASX listing rules, the Relevant Persons disclaim any obligation or undertaking to publicly update any statements in this presentation, whether as a result of new information or future events.

This presentation should not be relied on as a recommendation or forecast by Medibio Limited. Nothing in this presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

© 2019 Medibio Limited



We are a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions.

#### **Corporate Structure**

CAPITAL STRUCTURE (ASX:MEB) (OTCQB:MDBIF)

# Market Cap Share price as of 24 May 2019 Shares on Issue Shares on issue –fully diluted<sup>1</sup>

Cash<sup>1</sup>

1. Convertible notes have mandatory conversion June 2020

2. Cash balance as of 31 March 2019

AU\$2.79M

AU\$0.011 249M 138M AU\$2.9M medibio

LOOKING AT MENTAL HEALTH, OBJECTIVELY

# **Re-Startup Strategy**

Medibio's RE-STARTUP is progressing on plan:

- ✓ Restructured Board and Key Management
- ✓ New Cost Controls to Reduce Cash Burn
- ✓ Strengthened Regulatory Path
- $\checkmark$  Commercial launch of ilumen<sup>TM</sup>
  - Australia
  - Interest within U.S. growing quickly



# Board of Directors



DAVID B. KAYSEN Chair, Managing Director & CEO



PETER CARLISLE Lead Independent Director Managing Director, Olympics & Action Sports, Octagon Worldwide



DR FRANKLYN G PRENDERGAST PhD MD, Non Executive Board Member Former member board of Trustee and Board of Governors Mayo Clinic and board member Eli Lilly



PATRICK KENNEDY Non Executive Director Former US Congressman Founder, Kennedy Forum



MICHAEL PHELPS Non Executive Director Mental Health Advocate



CLAUDE SOLITARIO Non Executive Director Founding Shareholder 6



MELANIE LEYDIN Director & Joint Company Secretary B. Bus, CA



MATHEW WATKINS Joint Company Secretary B. Bus, CA

# **Executive Team**



DAVID B. KAYSEN Chair, Managing Director & CEO



PEGGY MORGAN Corporate Controller

ARCHIE DEFILLO Chief Medical Officer




JENNIFER SOLITARIO Senior Vice President Corporate Health



LINDSEY HAGAN Vice President Strategy & Business Development

# **Quarterly Cash Burn**



- January March represents actuals.
- Subsequent quarters represent projected cash burn.

# **Business Objectives – Regulated & Unregulated Product Pipeline**

Leverage recent ISO13485 re-certification with expanded scope • Finalise a revised CE Mark product no later than September 2019 **CE Mark Opportunities** Define commercialisation opportunities in the European Union Build strategic alliances/partnerships with Clinical Research 0 months Organisations (CRO), European Sleep Study Societies, and pharmaceutical companies Retained DuVal & Associates as FDA Counsel 6 Identified long-term FDA strategy **U.S. FDA Regulated** Filing new De Novo in late 2019 9 **Products** Next Provide an early screening tool for presence of depressive symptoms Use of data from existing clinical workflows (sleep studies) 0 Global ilumen<sup>™</sup> With success of pilots, will move to annual subscription-based pricing model • Work to integrate ilumen<sup>™</sup> into organisations with global distribution channels . Expansion Seek to generate revenue through annual license fees and royalties based on usage .onger Term Objectives Leverage U.S., Australian and European relationships - clinical partners, • Future universities/hospitals, Scientific Advisory Board Commercialisation U.S. FDA – decision on new De Novo submission expected late 2020 • Efforts

# **Product Overview – U.S. Regulated Pathway**

 FDA De Novo
 O
 O

 Submission
 Clearance
 Go to Market


De Novo to be filed in late CY2019 with end point anticipated in late CY2020

Improve Clinician assessment of patient's mental health

Company has begun positive and open dialogue with FDA

FDA is helping to guide us through the process and has provided excellent directional feedback about our technology.

# **Mental Health Diagnosis**



# Unlike diabetes or cancer - there is no medical test that can provide a diagnosis of mental illness



Mental Health - Diagnosis Delay


"Median delays among cases eventually making contact ranged from 3.0 to 30.0 years for anxiety disorders, from 1.0 to 14.0 years for mood disorders" *World Health Organization* 

> Of the population with MDD, only 35 percent are treated within the first year of developing symptoms; for others it can take 4 years or more. *Mental Health America*

"People with bipolar disorder wait for an average of 13.2 years before they are diagnosed, and often spend years receiving treatment for other conditions" *Royal College of Physicians* 



# **Circadian Rhythms and Mental Illness**



# Normal

# Depression

Anxiety

#### References:

The Relationship between Psychiatric Illness and the Circadian Pattern of Heart Rate - Stampfer, H. G. (1998). Australian and New Zealand Journal of Psychiatry.

Variations in circadian heart rate in psychiatric disorders: theoretical and practical implications - Stampfer, H. G. (2013). Chronophysiology and Therapy.


#### **New De Novo Submission**

New De Novo submission will have "Depressive Burden" as the indication of use. Depressive Burden is the cumulative load of depressive symptoms upon an individual.

The Beck Depression Inventory (BDI-II) is a measure of the severity of depression symptoms during a depressive episode. This is a subjective measure of depressive burden.

The use of the BDI-II is prevalent in many practices for the screening of depression, as well as polysomnography studies.

# The Biometrics – Used by Medibio's Proprietary Algorithms



### **Product Overview**

The Medibio Platform will integrate with existing sleep study systems to analyze multiple channels of physiological data to calculate a mental health risk score. A pipeline of products is planned which will offer additional mental health reporting features to the referring physician.



Step 1

Conduct a Polysomnography (PSG) study using existing data parameters and acquisition software and export the data as an EDF/+ file.

#### Step 2

Automatically transfer (or manually upload) the EDF/+ file to the secure server. Personal health information is automatically removed before the upload.

#### Step 3

Transferred file is processed in the cloud, analyzed and available for review in 15 minutes or less.

#### Step 4

Clinic technologists briefly review the file using viewer software and generate a report for the referring physician to review.

# U.S. Sleep Studies Market Data

- In 2015, 2,800 labs had an estimated \$7.1 billion in revenue. By 2020, the industry will be within the \$10 billion mark.<sup>1</sup>
- Average of 7.7 beds in each center<sup>2</sup>
- 5 nights a week
- ~ 4.4 million studies each year\*

 A mild sleep apnea sufferer is twice as likely to have depression.<sup>3</sup>

- 2. http://www.sleepreviewmag.com/2016/05/first-quarter-2016-sleep-center-survey-results/
- 3. https://www.novasom.com/for-patients/sleep-apnea-related-conditions/depression/

\* Assumes 80% utilisation

https://www.forbes.com/sites/daviddisalvo/2015/08/06/how-the-sleep-industry-is-making-billions-from-your-lack-of-shuteye/#349d60cf2542

# **Potential Commercialisation & Partnership Opportunities**

Company	Focus	Organization Revenue	Commercial Potential
Philips Respironics USA	Sleep and Respiratory Care	\$1.1B	Licensing, royalty fee per usage
ResMed Inc. USA	Sleep apnea, COPD, and other chronic diseases	\$2.3B	Licensing, royalty fee per usage
Natus Medical, Inc. USA	Polysomnography Software	\$500M	Licensing, royalty fee per usage
Compumedics, Ltd. Australia, China, Japan	Sleep Diagnostics	\$34.4M	Licensing, royalty fee per usage









# **Product Overview – Corporate Health**



ilumen

An objective digital biometric analysis and mental well-being assessment provided to the employee, paid for by their employer.

- Mental wellness survey and assessment
- · Biometric monitoring with history tracking
- Communications toolbox for rollout
- Organisational dashboard analytics
- Recommendations for employer

#### **THREE-STEP PROCESS**





## **Product Overview – Corporate Health**



- Detailed analytics to Corporate Customers at Organisational level
- · De-identified aggregate data to enable informed decision making
- · Improve team performance and employee well-being

# CORPORATE HEALTH



# **Product Overview – Corporate Health**



# WHY IT'S NEEDED


In any workforce there are various levels of stress that can affect individual/team mental well-being.

#### Employers are

- Increasing pressure to meet internal/external targets and promoting high performing culture
- Requiring higher levels of mental fitness & time requirements at work and at home
- Expecting frequent travel and project deployment

#### ...While managing

- Wide geographical distribution
- Turnover
- Well-being programs that aren't data-driven or specific to your organisation



#### Employees:

- Employees track biometrics over time with a wearable device
- Access to mental wellness assessments via mobile or web
- Empowered to measure, monitor, and improve well-being

#### Organisations:

- Dynamic understanding know what your workforce needs AND how to help
- Optimise workforce performance, minimise risk, and offer better care for employees



# CORPORATE HEALTH

# WHAT IT DOES

#### Employees:

- Track and monitor well-being
- Improve through access to resources
- Identify positive influences of personal lifestyle modifications

#### Organisations:

- Access a de-identified dashboard of employee well-being
- Make informed decisions based on workforce data
- Monitor impact of decisions made, programs implemented

# **Product Overview – Corporate Health Commercial Opportunities**



## Global ilumen™ in Corporate Health Market



App based system provides feedback to individual

 De-identified aggregate feedback to Corporate partner

Pilot programs marketed to large corporations with goal for annual license agreements.

- One pilot completed with high participation
- Proposal to engage for new 1-year program
- Per employee license fee pricing structure moving forward
- In discussion with large multinational company – 600,000+ employees

- Focus on Better Use
   of Biometrics
- Continue to Improve Biometric Algorithm (based on wearable data collected)



# **Product Overview – Corporate Health – Commercial Opportunities**

#### **Global Enquiries**

#### Corporations

• Well-being programs

#### Pharma Companies

Partnership/Development
 opportunities

#### Sports/Athletics

 Partnership/Development opportunities

#### **Commercial Potential**

#### Corporations

Per employee license fees

#### Pharma Companies

- Fee for specific development
- License fees for platform

#### Sports /Athletics

- Fee for specific development
- · License fees for platform

#### THREE-STEP PROCESS







CONNECT



DISCOVER

ilumen

medibio

**CORPORATE HEALTH** 

ilumen

# Milestones

# $\circ$ $\circ$ $\circ$

# CY 2019 Q3

- New ilumen<sup>™</sup> programs in AUS
- Potential 1-year program for ilumen<sup>™</sup>
- New CE Mark
- New Clinical Partnership with world renowned university sleep research center
- Published research and white papers

# CY 2019 Q4

٠

- New De Novo submission filed with FDA
- Potential first sports client for ilumen<sup>™</sup>
- Published research and white papers

# CY 2020 Q1

- Potential first U.S. ilumen<sup>™</sup> client
- Published research and white papers

# CY 2020 Q3

- FDA De Novo
   Clearance
- Published research and white papers

# medibio

#### **THANK YOU**

8696 Eagle Creek Circle Savage, MN 55378 USA **medibio.com.au** 

LOOKING AT MENTAL HEALTH, OBJECTIVELY